JP2017535246A5 - - Google Patents

Download PDF

Info

Publication number
JP2017535246A5
JP2017535246A5 JP2017512808A JP2017512808A JP2017535246A5 JP 2017535246 A5 JP2017535246 A5 JP 2017535246A5 JP 2017512808 A JP2017512808 A JP 2017512808A JP 2017512808 A JP2017512808 A JP 2017512808A JP 2017535246 A5 JP2017535246 A5 JP 2017535246A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017512808A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535246A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/048659 external-priority patent/WO2016037119A1/en
Publication of JP2017535246A publication Critical patent/JP2017535246A/ja
Publication of JP2017535246A5 publication Critical patent/JP2017535246A5/ja
Pending legal-status Critical Current

Links

JP2017512808A 2014-09-05 2015-09-04 新規の抗mfi2抗体および使用方法 Pending JP2017535246A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462046610P 2014-09-05 2014-09-05
US62/046,610 2014-09-05
US201562203836P 2015-08-11 2015-08-11
US62/203,836 2015-08-11
PCT/US2015/048659 WO2016037119A1 (en) 2014-09-05 2015-09-04 Novel anti-mfi2 antibodies and methods of use

Publications (2)

Publication Number Publication Date
JP2017535246A JP2017535246A (ja) 2017-11-30
JP2017535246A5 true JP2017535246A5 (enExample) 2019-04-25

Family

ID=55440418

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512808A Pending JP2017535246A (ja) 2014-09-05 2015-09-04 新規の抗mfi2抗体および使用方法

Country Status (22)

Country Link
US (1) US10428156B2 (enExample)
EP (1) EP3189079A4 (enExample)
JP (1) JP2017535246A (enExample)
KR (1) KR20170045351A (enExample)
CN (1) CN107001454A (enExample)
AU (1) AU2015311743A1 (enExample)
BR (1) BR112017004444A2 (enExample)
CA (1) CA2959705A1 (enExample)
CL (2) CL2017000506A1 (enExample)
CO (1) CO2017003005A2 (enExample)
CR (1) CR20170117A (enExample)
DO (1) DOP2017000052A (enExample)
EA (1) EA201790529A1 (enExample)
IL (1) IL250825A0 (enExample)
MA (1) MA40612A (enExample)
MX (1) MX2017002862A (enExample)
PE (1) PE20170776A1 (enExample)
PH (1) PH12017500406A1 (enExample)
SG (1) SG11201701650PA (enExample)
TW (1) TW201617368A (enExample)
WO (1) WO2016037119A1 (enExample)
ZA (1) ZA201701674B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069633A (zh) * 2016-04-15 2018-12-21 宏观基因有限公司 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
WO2019167874A1 (ja) * 2018-02-27 2019-09-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 Apoa4に対するモノクローナル抗体、免疫学的測定方法及び測定用キット
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
WO2020021556A1 (en) * 2018-07-26 2020-01-30 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions targeting gabra2 and methods for diagnosis and treatment of cancer
US20220023433A1 (en) * 2018-12-21 2022-01-27 Sapreme Technologies B.V. Saponin Conjugates
CN109709340B (zh) * 2018-12-29 2022-02-11 江苏众红生物工程创药研究院有限公司 人中性粒细胞明胶酶相关脂质运载蛋白定量检测卡及其临床应用
WO2020150282A1 (en) * 2019-01-18 2020-07-23 Askgene Pharma Inc. Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis
JP7754715B2 (ja) * 2019-02-05 2025-10-15 シージェン インコーポレイテッド 抗cd228抗体及び抗体薬物コンジュゲート
US12678067B1 (en) 2019-03-20 2026-07-14 Biological Art Group, Inc. Telemetry implants
US12435131B2 (en) 2019-07-11 2025-10-07 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
GB201913594D0 (en) * 2019-09-20 2019-11-06 Univ Birmingham Epigenetic profiling method
US11834512B2 (en) * 2020-05-04 2023-12-05 The Regents Of The University Of California Inhibiting anti-ENPP1 antibodies
CN111909933B (zh) * 2020-06-29 2021-07-02 浙江大学 靶向细胞表面抗原mfi2蛋白的核酸适配体及应用
AU2021320739A1 (en) * 2020-08-04 2023-02-23 Seagen Inc. Anti-CD228 antibodies and antibody-drug conjugates
WO2022187050A1 (en) * 2021-03-01 2022-09-09 BioLegend, Inc. Anti-cd117 agents and compositions and methods for making and using the same
CN116925216B (zh) * 2022-04-11 2024-09-24 东莞市朋志生物科技有限公司 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒
WO2023231877A1 (zh) * 2022-05-31 2023-12-07 山东博安生物技术股份有限公司 抗cd228抗体及其药物偶联物
WO2024064714A2 (en) * 2022-09-21 2024-03-28 Seagen Inc. Antibodies that bind cd228
CN121620532A (zh) * 2023-07-28 2026-03-06 山东博安生物技术股份有限公司 一种适用于免疫组化检测cd228的诊断抗体
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
USRE38008E1 (en) 1986-10-09 2003-02-25 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5191066A (en) 1990-12-07 1993-03-02 Abbott Laboratories Site-specific conjugation of immunoglobulins and detectable labels
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US6146850A (en) 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5981194A (en) 1992-07-10 1999-11-09 University Of British Columbia Use of p97 and iron binding proteins as diagnostic and therapeutic agents
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
CA2250118C (en) 1996-03-26 2009-09-29 Michael S. Kopreski Method enabling use of extracellular rna extracted from plasma or serum to detect, monitor or evaluate cancer
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
WO1999037779A1 (en) 1998-01-22 1999-07-29 Genentech, Inc. Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
ES2260570T3 (es) 1998-08-27 2006-11-01 Spirogen Limited Pirrolobenziodiazepinas dimericas.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
JP4414023B2 (ja) * 1999-08-05 2010-02-10 オリエンタル酵母工業株式会社 関節炎関連メラノトランスフェリンの測定方法および試薬
EP1285272A2 (en) 2000-02-08 2003-02-26 University of British Columbia Compositions and methods for screening therapeutic agents
KR20020007432A (ko) 2000-07-13 2002-01-29 박현석 멜라노트랜스페린에 대한 단클론 항체를 유효성분으로포함하는 알츠하이머병의 진단시약
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US6362331B1 (en) 2001-03-30 2002-03-26 Council Of Scientific And Industrial Research Process for the preparation of antitumor agents
EP1256354A1 (en) 2001-05-11 2002-11-13 Schering Corporation Methods for treating cancer
TW200303759A (en) 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
MXPA05004677A (es) 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
EP1419786A1 (en) 2002-11-13 2004-05-19 Bracco Imaging S.p.A. Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof
GB0226593D0 (en) 2002-11-14 2002-12-24 Consultants Ltd Compounds
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7919103B2 (en) * 2003-05-09 2011-04-05 Transfert Plus Compound and method for regulating plasminogen activation and cell migration
US7619068B2 (en) 2003-05-09 2009-11-17 Diadexus, Inc. Ovr110 antibody compositions and methods of use
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
AU2004273791A1 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
GB0321295D0 (en) 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
US7807392B1 (en) 2003-09-15 2010-10-05 Celera Corporation Lung disease targets and uses thereof
ES2398975T3 (es) 2004-03-01 2013-03-25 Spirogen Sàrl Derivados de 11-hidroxi-5H-pirrolo[2,1-c][1,4]benzodiazepin-5-ona como intermedios clave para la preparación de pirrolobenzodiazepinas sustituidas en C2
GB0404577D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
US7837980B2 (en) 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
US7189710B2 (en) 2004-03-30 2007-03-13 Council Of Scientific And Industrial Research C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers
FR2869231B1 (fr) 2004-04-27 2008-03-14 Sod Conseils Rech Applic Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
US20080305044A1 (en) 2004-11-29 2008-12-11 Seattle Genetics, Inc. Engineered Antibodies and Immunoconjugates
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
CA2606081C (en) 2005-04-26 2013-09-17 Markus M. Heiss Combination of the application of antibodies for immunostimulation together with glucocorticoids
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
US7521195B1 (en) 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof
US20070123448A1 (en) 2005-11-23 2007-05-31 The Hospital For Sick Children Novel chemical entities affecting neuroblastoma tumor-initiating cells
DK1813614T3 (da) 2006-01-25 2012-01-23 Sanofi Sa Cytotoksiske midler, der omfatter nye tomaymycinderivater
PT2032606E (pt) 2006-05-30 2014-02-05 Genentech Inc Anticorpos e imunoconjugados e respetivas utilizações
WO2007145901A1 (en) 2006-06-06 2007-12-21 University Of Tennessee Research Foundation Compositions enriched in neoplastic stem cells and methods comprising same
US20080220448A1 (en) 2006-09-01 2008-09-11 Blincko Stuart J Antigenic protein conjugates and process for preparing same
EP3207941B3 (en) 2006-09-07 2020-08-19 Scott & White Memorial Hospital Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
WO2008091908A2 (en) 2007-01-22 2008-07-31 Raven Biotechnologies Human cancer stem cells
PE20090245A1 (es) 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
EP2022848A1 (en) 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
CA2697922A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
JP5963341B2 (ja) 2007-09-14 2016-08-10 アムジエン・インコーポレーテツド 均質な抗体集団
WO2009043051A2 (en) 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
KR20100107501A (ko) 2008-01-18 2010-10-05 메디뮨 엘엘씨 부위 특이적 접합을 위한 시스테인 조작 항체
US20100162416A1 (en) 2008-09-29 2010-06-24 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
TWI544077B (zh) 2009-03-19 2016-08-01 中外製藥股份有限公司 Antibody constant region change body
US20110020221A1 (en) 2009-04-09 2011-01-27 The Johns Hopkins University Cancer stem cell expression patterns and compounds to target cancer stem cells
LT2536399T (lt) 2010-02-21 2020-03-10 Bayer Healthcare Llc Biomolekulių aktyvinimo ir konjugavimo būdas
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
MX368648B (es) 2010-04-15 2019-10-09 Seattle Genetics Inc Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas.
CN103068405A (zh) * 2010-04-15 2013-04-24 西雅图基因公司 靶向吡咯并苯并二氮杂卓结合物
GB201006340D0 (en) 2010-04-15 2010-06-02 Spirogen Ltd Synthesis method and intermediates
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2013119964A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
CA2809864A1 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
US20130061340A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
US20130061342A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
WO2012036094A1 (ja) 2010-09-17 2012-03-22 独立行政法人産業技術総合研究所 肺癌鑑別マーカー
JP6014596B2 (ja) 2010-11-09 2016-10-25 メディミューン,エルエルシー 均一コンジュゲーションのための抗体足場
EP2648751A4 (en) 2010-12-09 2015-04-15 Bayer Healthcare Llc DIMERE MOLECULAR COMPLEXES WITH FREE CYSTEIN RESTANTS AND CONJUGATES THEREOF
KR101981342B1 (ko) 2011-03-02 2019-05-22 로슈 글리카트 아게 Cea 항체
AU2012278944B2 (en) * 2011-07-05 2015-09-17 Bioasis Technologies Inc. p97-antibody conjugates and methods of use
CA2842492A1 (en) 2011-08-05 2013-02-14 Bioasis Technologies, Inc. P97 fragments with transfer activity
EP2768852A4 (en) 2011-10-19 2015-05-13 Theratechnologies Inc PEPTIDE COMPOUNDS FROM MELANOTRANSFERRINE AND USES THEREOF
KR20110136776A (ko) * 2011-12-12 2011-12-21 경북대학교 산학협력단 당뇨병성 신증 진단용 바이오마커 및 이의 동정방법
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
EP3539982B1 (en) 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
RU2691698C2 (ru) 2012-02-24 2019-06-17 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Антитела против sez6 и способы их применения
CA2866612C (en) * 2012-03-08 2018-01-16 Halozyme, Inc. Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
WO2013177481A1 (en) * 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
NZ705040A (en) * 2012-07-20 2017-07-28 Cleave Biosciences Inc Fused pyrimidines as inhibitors of p97 complex
WO2014054804A1 (ja) 2012-10-05 2014-04-10 協和発酵キリン株式会社 ヘテロダイマータンパク質組成物
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
PT2906248T (pt) 2012-10-12 2019-03-04 Medimmune Ltd Pirrolobenzodiazepinas e conjugados das mesmas
EA201591465A1 (ru) 2013-02-08 2015-12-30 АйАрЭм ЭлЭлСи Специфичные участки для модификации антител для получения иммуноконъюгатов
ES2731681T3 (es) 2013-02-22 2019-11-18 Abbvie Stemcentrx Llc Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
NZ711373A (en) 2013-03-13 2020-07-31 Bioasis Technologies Inc Fragments of p97 and uses thereof
BR112015030514A2 (pt) 2013-06-04 2017-08-29 Cytomx Therapeutics Inc Composições e métodos para conjugação de anticorpos ativáveis
CA2912389C (en) 2013-06-10 2020-01-28 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods and compositions for reducing immunosupression by tumor cells
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
JP2016531915A (ja) 2013-08-28 2016-10-13 ステムセントリックス, インコーポレイテッド 部位特異的抗体コンジュゲーション方法および組成物
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
MX2016010295A (es) 2014-02-11 2016-10-17 Seattle Genetics Inc Reduccion selectiva de proteinas.
EP3107576A4 (en) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
US20190209704A1 (en) 2014-10-20 2019-07-11 Igenica Biotherapeutics, Inc. Novel antibody-drug conjugates and related compounds, compositions and methods of use

Similar Documents

Publication Publication Date Title
US9353182B2 (en) Anti-DLL3 antibodies
ES2763548T3 (es) Anticuerpos anti-TIM3 y procedimientos de uso
JP7657213B2 (ja) 抗メソテリンエリブリン抗体-薬物コンジュゲート及び使用方法
US10428156B2 (en) Anti-MFI2 antibodies and methods of use
JP2018127469A5 (enExample)
JP2016531915A5 (enExample)
JP2016531914A5 (enExample)
JP2019532056A5 (enExample)
KR20160070191A (ko) 신규한 항-클라우딘 항체 및 사용 방법
JP2018529656A (ja) 抗dll3抗体薬物コンジュゲートおよび使用方法
KR20160097336A (ko) 신규 항-dpep3 항체 및 이의 사용 방법
JP2016536020A5 (enExample)
CN110494448B (zh) 包含抗-ly75抗体的医药组合
ES3007557T3 (en) Anti-edb antibodies and antibody-drug conjugates
KR20180088445A (ko) 신규한 항-클라우딘 항체 및 사용 방법
KR20160047567A (ko) 조작된 항-dll3 접합체 및 사용 방법
JP2020502271A (ja) 抗cubドメイン含有タンパク質1(cdcp1)抗体、抗体薬物コンジュゲート、およびその使用方法
AU2017267789A1 (en) Anti-DLL3 drug conjugates for treating tumors at risk of neuroendocrine transition
JP2015509948A5 (enExample)
CN108290949A (zh) 对asct2具有特异性的结合分子及其用途
AU2016355206A1 (en) Novel anti-EMR2 antibodies and methods of use
JP7578289B2 (ja) Muc18に特異的な抗体
JP2019511199A (ja) 新規の抗upk1b抗体及び使用方法
AU2017261369A1 (en) Novel anti-TNFRSF21 antibodies and methods of use
TW202542193A (zh) 抗原結合分子、其藥物偶聯物及其醫藥用途